One randomized clinical trial reported that low dose rhEPO intravenous treatment significantly decreased the incidence of retinopathy of prematurity, an effect of preterm hypoxia, in infant boys (Sun et al., 2020), while many other studies focused on demonstrating that such oxidative damage was not related to EPO concentrations. The gene discussed is EPO; the disease is retinopathy of prematurity.